Trial Profile
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Docetaxel
- Indications Brain metastases; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms LATIFY
- Sponsors AstraZeneca
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 25 May 2023 According to an AstraZeneca media release, trial-in-progress poster will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.
- 14 Mar 2023 Planned End Date changed from 4 Jun 2025 to 22 May 2025.